MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.

David P. Steensma, Jonathan S.C. Caudill, Animesh Pardanani, Rebecca F. McClure, Terra L. Lasho, Ayalew Tefferi

Research output: Contribution to journalArticle

15 Scopus citations


Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.

Original languageEnglish (US)
Pages (from-to)ECR57
Issue number12 Suppl
StatePublished - Dec 2006


ASJC Scopus subject areas

  • Hematology

Cite this